Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Group vs. Individual MDMA-Assisted Therapy in PTSD Patients Diagnosed Following the Events of October 7, 2023
NCT07469098Phase 2Recruiting
- Sponsor
- Sheba Medical Center
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Sheba Medical Center. Primary endpoints: Clinician-Administered PTSD Scale for DSM-5 at Week 17 and PTSD Checklist for DSM-5 at Week 17. Started Dec 2025; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07469098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469098.